VICTORIA, Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a
provider of best-in-class therapeutic antibody discovery
capabilities for the global industry, today announced the
appointment of Brian Lundstrom to
the company's Board of Directors. Dr. James
Kuo, ImmunoPrecise Chairman, noted: "With the addition of
Mr. Lundstrom, ImmunoPrecise further strengthens its strategic and
operational commitment to industry-leading therapeutic antibody
discovery for both its clients and the company's emerging internal
pipeline."
![ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1005597/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_Strengthens_Board_of.jpg)
Trained in immunology and international business, Mr. Lundstrom
has over 30 years' experience from mostly publicly traded companies
with a focus on antibody therapeutics. He started his career with
product and clinical development for Novo Nordisk, in Europe, in 1987 and moved to the US in 1993 to
form a dedicated business development function. He subsequently
served as business development and financing lead for publicly
traded companies such as OGS (now UCB), SangStat (now a Division of
Sanofi Genzyme), ACADIA and ISCO. This included SangStat's
$600M sale and integration into
Genzyme in 2003.
Since 2011, Mr. Lundstrom has established global business
leadership in transgenic animals for discovery of human therapeutic
antibodies, first with OMT, and then with Ligand Pharmaceuticals
Incorporated (NASDAQ:LGND), after their $178M acquisition of OMT.
"We welcome Brian Lundstrom to
our board and consider his immense experience in developing and
closing pharma partnerships as a tremendous benefit to the company,
as ImmunoPrecise continues to take stage as a leader in
data-driven, therapeutic antibody discovery," said Dr.
Jennifer Bath, President and CEO of
ImmunoPrecise.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell SelectTM progressive single-cell
interrogation technology and the DeepDisplayTM custom,
OmniAb-based phage libraries, as well as the AbthenaTM
bispecific program. IPA is focused on the next generation of
antibody discovery, to deliver the most therapeutically-relevant
antibodies, in a shorter period of time, with the highest
probability of succeeding to clinical trials.
ImmunoPrecise discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria, British Columbia (IPA Canada). The Company
operates globally to offer a continuum of superior antibody
services, transforming the face of therapeutic discovery, by
decreasing turnaround time and risk, and promoting clinical
success.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.